SecBot SecBot
8-K ·Filed Nov 5, 2026

PVLA

PALVELLA THERAPEUTICS, INC.
BULLISH
Impact 7/10
Horizonmonths Processed11d 20h ago SEC0001193125-26-448594
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The PDUFA date of February 28, 2027 is the next major catalyst. Monitor for any FDA advisory committee meeting announcements or complete response letter risks. The company's cash position of $236.7M appears sufficient to fund operations through the PDUFA date and initial launch preparations.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$156.85
T+0 close · Nov 5, 2026 · via day close
Latest settled
−2.34%
T+5 · $153.18
Vs SPY
−5.63%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $156.85entry
  2. T+1 · 11d ago +12.16%α +11.85% · $175.92
  3. T+5 · 5d ago −2.34%α −5.63% · $153.18
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Palvella reported Q3 2026 results with a net loss of $24.6M ($1.70/share), wider than the $11.3M loss in Q3 2025, as R&D and G&A expenses increased. The key event is the FDA's acceptance of the NDA for QTORIN rapamycin in microcystic lymphatic malformations with Priority Review and a PDUFA date of February 28, 2027, bringing the company closer to a potential first FDA-approved therapy for this indication.

Key Financial Metrics

EPS
−$1.70

Key Facts

  • FDA accepted NDA for QTORIN rapamycin for microcystic lymphatic malformations with Priority Review; PDUFA target action date February 28, 2027
  • Cash, cash equivalents and short-term investments of $236.7 million as of September 30, 2026
  • Net loss of $24.6 million ($1.70 per share) for Q3 2026, compared to net loss of $11.3 million ($1.03 per share) for Q3 2025
  • Research and development expenses of $10.8 million for Q3 2026, up from $6.5 million in Q3 2025
  • General and administrative expenses of $11.9 million for Q3 2026, up from $3.6 million in Q3 2025
  • Phase 3 trial initiation for cutaneous venous malformations on track for Q4 2026
  • Phase 2 trial initiation for DSAP expected in Q4 2026
  • Two additional pipeline programs anticipated to be announced by year-end 2026

Financial Impact

Net loss increased to $24.6M in Q3 2026 from $11.3M in Q3 2025, driven by higher R&D and G&A costs as the company advanced its NDA submission and built commercial infrastructure. Cash burn is expected to continue as the company prepares for a potential launch in 1H 2027.

net losscashR&D expensesG&A expenses

Risk Factors

  • FDA may issue a complete response letter or require additional clinical data before approval
  • Commercial launch execution risk if approved, as Palvella has no prior commercial experience
  • Increasing operating losses as the company scales up commercial and medical affairs teams
  • Pipeline programs are still in early stages and may not succeed

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-448594
Document: pvla-20261105.htm0001193125-26-448594
Document: pvla-ex99_2.htm0001193125-26-448594
Document: 0001193125-26-448594-index-headers.html0001193125-26-448594
Document: 0001193125-26-448594-index.html0001193125-26-448594
Document: 0001193125-26-448594.txt0001193125-26-448594
8-K Data (Synthetic)0001193125-26-448594

Track record

36 reports on PVLA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
  2. Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
  3. Nov 5, 202611d ago 8-K Bullish 7/10 Viewing Entry $156.85 Now $144.60 −7.81% settles Dec 4
  4. Nov 5, 202611d ago Press Release Neutral 6/10 No price data
  5. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
  6. Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  7. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  8. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  9. Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
  10. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 5h 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026